Disclosure of Interests: None declared

AB0291D

PREDICTORS OF NEW BONE EROSION IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING csDMARDs: ANALYSIS OF DATA FROM THE DRIVE AND DESIRABLE STUDIES

Tsurutomo Takeuchi1, Satoshi Soen2, Naoki Ishiguro3, Hisashi Yamanaka4, Saka Tanaka5, Mikako Kobayashi6, Naoki Okubo7, Makita Nitta8, Yoshiya Tanaka9, Keio University, Tokyo, Japan; 2Nara Hospital, Kinki University School of Medicine, Ikaru, Japan; 3Nagoya University, Nagoya, Japan; 4Tokyo Women’s Medical University, Tokyo, Japan; 5The University of Tokyo, Tokyo, Japan; 6Daiichi Sankyo Co., Ltd, Tokyo, Japan; 7University of Occupational and Environmental Health, Kitakyushu, Japan

Background: Suppression of joint destruction is an important target for the treatment of rheumatoid arthritis (RA). Most previous studies have proposed prediction models for joint destruction to detect the risk of rapid radiographic progression (change in mTSS ≥ 5). As joint destruction progresses irreversibly, even slight progression of joint destruction might impact the prognosis. Therefore, our study focused on the onset of new bone erosion in RA patients.

Objectives: To clarify predictors for new bone erosion in RA patients treated with csDMARDs.

Methods: Predictive factors were analyzed using data from the placebo groups of the DRIVE [1] and DESIRABLE [2] studies, which were 12-month, randomized, double-blind, phase 2 and 3 trials for evaluating the efficacy of denosumab in RA patients. New bone erosion was defined as change from baseline in erosion score (ES) ≥ 1.0 at 12 months, which was assessed as “progressed” by two readers. In addition to newly emerging erosion, new bone erosion also included enlargement of erosion size which is the result of new erosion at a site adjacent to an existing bone erosion. To evaluate predictors for new bone erosion, a logistic regression model was applied. Significant predictors (p value of <0.1) were selected from the univariate analysis and one variable from each correlated pair that showed significance was removed. Multivariate analyses were performed using the selected predictors.

Results: In a total of 306 patients, baseline DAS28-ESR (mean±SD) was 3.58±1.03. New bone erosion was observed in 90 patients (29.4%). In the univariate analysis, female sex, anti-CCP antibody positivity, rheumatoid factor (RF) positivity, tender joint count (TJC) ≥ 6, CRP > 0.3 mg/dL, erythrocyte sedimentation rate (ESR) > 28 mm/h, and baseline ES ≥ 3 were identified as significant predictors for new bone erosion. RF and ESR were not included in the multivariate analysis because they were strongly correlated with anti-CCP antibody and CRP, respectively. In the multivariate analyses, female sex, anti-CCP antibody positivity, TJC ≥ 6, CRP > 0.3 mg/dL, and baseline ES ≥ 3 were identified as predictors for the development of new bone erosion.

Abstract AB0291D Table 1. Univariate and multivariate analyses for a change in ES ≥ 1.0

<table>
<thead>
<tr>
<th>Variables</th>
<th>Univariate</th>
<th>Multivariate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Fem</td>
<td>Male</td>
</tr>
<tr>
<td>Age</td>
<td>≥ 65 years</td>
<td>&lt;65 years</td>
</tr>
<tr>
<td>Duration of disease</td>
<td>≥3 years</td>
<td>&lt;3 years</td>
</tr>
<tr>
<td>Anti-CCP antibody</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>RF</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Glucocorticoid use</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>TJC</td>
<td>≥6</td>
<td>&lt;6</td>
</tr>
<tr>
<td>Swollen joint count</td>
<td>≥10</td>
<td>&lt;10</td>
</tr>
<tr>
<td>CRP</td>
<td>≥0.3 mg/dL</td>
<td>&lt;0.3 mg/dL</td>
</tr>
<tr>
<td>ESR</td>
<td>≥28 mm/h</td>
<td>&lt;28 mm/h</td>
</tr>
<tr>
<td>Baseline ES</td>
<td>≥3</td>
<td>&lt;3</td>
</tr>
<tr>
<td>Study</td>
<td>DRIVE</td>
<td>DESIRABLE</td>
</tr>
</tbody>
</table>

Conclusion: In RA patients whose disease activity was controlled on csDMARDs, positive anti-CCP antibody/RF status, elevated CRP/ESR levels, baseline ES ≥ 3, TJC ≥ 6 and female sex were identified as predictors for new bone erosion.

REFERENCES
Background: Umbilical cord mesenchymal stem cells (UCMSCs) were cultured in vitro and separated using a differential centrifugation methods. The CIA rats model was set up by Freund’s complete adjuvant and type II collagen, then randomly divided into control, CIA, MTX, UCMSC, UCMSC and UCMSC-derived exosomes on chemokines have less understood in RA.

Objectives: The aim of this study was to investigate the effect of UCMSC and UCMSC-derived exosomes on the chemokines CCL2, CXCL10 and CXCL12 in CIA rats.

Methods: Human umbilical cord mesenchymal stem cells (UCMSCs) were prepared from umbilical cords of newborns and cultured in StemPro-34 medium. The cells were then treated with 10% FBS to induce cell differentiation and collect mesenchymal stem cells. UCMSCs were injected in double ankle joint with UCMSCs 2×10⁶/L weekly for 3 weeks. Rats in UCMSCs group were injected in double ankle joint with UCMSCs 2×10⁶/L weekly for 3 weeks. Rats in UCMSCs exosomes low and high group were injected in double ankle joint with UCMSCs exosomes 30μg and 90μg weekly for 3 weeks, respectively. Rats in MTX group were given intraperitoneal injection with MTX (0.9mg/kg) weekly for 3 weeks. Serum concentrations of CCL2 and CXCL10 were detected by flow cytometry. CXCL12 serum level was tested by enzyme-linked immunosorbent assay (ELISA). The protein expressions of synovial tissue and CCL2, CXCL10 and CXCL12 RNA levels in synovial joint and spleen were measured by reverse transcription-polymerase chain reaction (RT-PCR).

Results: Intra-articular injection of UCMSC exosomes decreased CCL2 and CXCL12 levels in serum and improved synovial hyperplasia and inflammatory cell infiltration in the CIA rats. UCMSC exosomes suppressed the protein expressions of CCL2, CXCL10, CXCL12 in synovial tissue. It also inhibited transcript levels of CCL2, CXCL10, CXCL12 in synovial tissue and spleen. UCMSC had similar effect on CCL2, CXCL10, CXCL12 in CIA. The high concentration group was more effective than the low concentration in preventing CCL2/CXCL10/CXCL12 protein expressions of synovial tissue and CCL2 transcript level of spleen.

Conclusion: UCMSC exosomes alleviates synovial inflammation in CIA rats through suppression of CCL2/CXCL10/CXCL12 release. The inhibitory effect of on chemokines simulate UCMSC, their cell of origin, the chemokines in collagen-induced arthritic rats.

REFERENCES

Disclosure of Interests: None declared


**Rheumatoid arthritis - comorbidity and clinical aspects**

**AB0292**

Effects of Acetaminophen on the Kidney Functions of Patients with Musculoskeletal Disease Treated with Long-Term Nonsteroidal Anti-Inflammatory Drug Therapy

Toshiaki Aizawa1, Tatekawa Kawano1, Takeshi Kishiwagura2, Naohisa Miyakoshi2, Yoichi Shimada3. Kitaakita Municipal Hospital, Akita, Japan; 2Akita City Hospital, Akita, Japan; 3Akita University Graduate School of Medicine, Akita, Japan

Background: While nonsteroidal anti-inflammatory drugs (NSAIDs) are the most frequently used therapeutic agents, they are known to cause side effects, such as gastrointestinal disorders and kidney dysfunction. As the proportion of patients with chronic kidney disease (CKD) increases with age, dealing with NSAIDs requires particular care in areas with aging populations. However, in many cases, prescriptions are continued without any particular plan. Hence, the effects of acetaminophen (AAP), which does not cause kidney dysfunction, are being revisited. Opportunities are increasing for using formulations containing tramadol hydrochloride in patients with chronic pain or intravenous agents for perioperative pain management.

Objectives: In this study, we investigated the kidney functions of patients with musculoskeletal disease who had been using NSAIDs for a long time and examined the possibility of switching to AAP.

Methods: The subjects were 105 patients with musculoskeletal disease (42 men and 63 women) who were being treated as outpatients in the orthopedics department of our hospital and had been using NSAIDs for at least 3 months. They primarily had 5 musculoskeletal diseases, including degenerative osteoarthritis (OA), rheumatoid arthritis (RA), osteoporosis (OP), polymyalgia rheumatica (PMR), and gout (G). After checking their background characteristics, we measured their kidney functions and visual analogue scale (VAS) scores, and then switched them from NSAIDs to AAP. Kidney functions were evaluated by classifying CKD using glomerular filtration rate (eGFR) and urinary protein, and by using the Cockcroft-Gault equation to calculate creatinine clearance (Ccr). The patients were given the NSAIDs that they had been taking for single use. Six months after the switch, we reassessed kidney functions and VAS scores, and investigated whether they could continue using AAP and whether they had used NSAIDs.

Results: The patients’ mean age at the time of switching from NSAIDs to AAP was 76 years, and their mean duration of NSAID use was 43 months. For the diseases, 63 patients had OA, 20 had RA, 14 had OP, 6 had PMR, and 2 had G. Before the switch, the mean VAS score was 41.6 mm and mean eGFR was 67.0 mL/min/1.73 m². On the basis of the eGFR, the CKD classification was G3 or higher in 38.1% of patients. The CKD classifications with the amounts of urine protein added to the eGFR were as follows: green, 44.7%; yellow, 33.0%; orange, 14.6%; and red, 7.8%, with 55.4% classified as having CKD. By age, the proportions of patients with CKD based on eGFR and CKD classification were as follows, respectively: 0.0% and 12.5% for those in their 50s, 16.7% and 25.0% for those in their 60s, 29.3% and 48.8% for those in their 70s, and 59.5% and 69.0% for those in their 80s and older. The mean AAP dose was 455 mg.

Six months after the switch, 69 patients had continuously used AAP without regular NSAID use. Of these patients, 13 had used NSAIDs for rescue purposes. Thirty-six patients had stopped using AAP, the most common reason being ineffectiveness (15 patients), although none stopped because of liver dysfunction. Overall, the mean VAS score declined significantly with comparison before the switch, as did the mean eGFR. Of those who continued to use AAP, 56 patients who did not use any NSAIDs exhibited significantly lower mean VAS scores, but not a significant decline in mean eGFR.

Conclusion: The proportion of patients with CKD who were receiving long-term NSAID therapy was higher than that of the general population for all age groups. Halting NSAIDs and switching to AAP could help maintain kidney functions, which could continue to decline with NSAID use.

Disclosures of Interests: None declared

REFERENCES
[1] CKD guidebook;2012